Black Diamond Therapeutics (BDTX) Stock Forecast, Price Target & Predictions
BDTX Stock Forecast
Black Diamond Therapeutics stock forecast is as follows: an average price target of $14.75 (represents a 507.00% upside from BDTX’s last price of $2.43) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
BDTX Price Target
The average price target for Black Diamond Therapeutics (BDTX) is $14.75 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $20.00 to $11.00. This represents a potential 507.00% upside from BDTX's last price of $2.43.
BDTX Analyst Ratings
According to 5 Wall Street analysts, Black Diamond Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for BDTX stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Black Diamond Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 31, 2024 | Laura Prendergast | Raymond James | $20.00 | $5.91 | 238.41% | 723.05% |
| Jun 03, 2024 | Joseph Calanzaro | Piper Sandler | $12.00 | $4.78 | 150.84% | 393.83% |
| May 16, 2024 | Robert Burns | H.C. Wainwright | $11.00 | $5.44 | 102.21% | 352.67% |
| Apr 08, 2024 | Robert Driscoll | Wedbush | $16.00 | $5.06 | 216.21% | 558.44% |
| Mar 18, 2024 | Raghuram Selvaraju | H.C. Wainwright | $12.00 | $4.70 | 155.32% | 393.83% |
The latest Black Diamond Therapeutics stock forecast, released on Jul 31, 2024 by Laura Prendergast from Raymond James, set a price target of $20.00, which represents a 238.41% increase from the stock price at the time of the forecast ($5.91), and a 723.05% increase from BDTX last price ($2.43).
Black Diamond Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 5 |
| Avg Price Target | - | - | $14.20 |
| Last Closing Price | $2.43 | $2.43 | $2.43 |
| Upside/Downside | -100.00% | -100.00% | 484.36% |
In the current month, the average price target of Black Diamond Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Black Diamond Therapeutics's last price of $2.43. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 23, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 18, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 10, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 30, 2024 | Raymond James | - | Outperform | Initialise |
| Jun 03, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 08, 2024 | Wedbush | Outperform | Outperform | Hold |
| Jun 28, 2023 | H.C. Wainwright | - | Buy | Upgrade |
| Jun 27, 2023 | Wedbush | - | Outperform | Upgrade |
Black Diamond Therapeutics's last stock rating was published by Cowen & Co. on Sep 23, 2024. The company gave BDTX a "Buy" rating, the same as its previous rate.
Black Diamond Therapeutics Financial Forecast
Black Diamond Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Black Diamond Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. BDTX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Black Diamond Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict BDTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Black Diamond Therapeutics's previous annual EBITDA (undefined) of $NaN.
Black Diamond Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-9.61M | $-9.61M | $-13.00M | $-12.43M | $-19.02M | $-17.99M | $-17.05M | $-16.58M | $-17.76M | $-21.10M | $-21.34M |
| High Forecast | $-9.61M | $-9.61M | $-13.00M | $-12.43M | $-19.02M | $-17.99M | $-17.05M | $-10.69M | $-14.32M | $-21.10M | $-21.34M |
| Low Forecast | $-9.61M | $-9.61M | $-13.00M | $-12.43M | $-19.02M | $-17.99M | $-17.05M | $-23.53M | $-20.62M | $-21.10M | $-21.34M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Black Diamond Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BDTX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Black Diamond Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Black Diamond Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to BDTX last annual SG&A of $NaN (undefined).
Black Diamond Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.17 | $-0.17 | $-0.23 | $-0.22 | $-0.34 | $-0.32 | $-0.30 | $-0.29 | $-0.31 | $-0.37 | $-0.39 |
| High Forecast | $-0.17 | $-0.17 | $-0.23 | $-0.22 | $-0.34 | $-0.32 | $-0.30 | $-0.19 | $-0.25 | $-0.37 | $-0.39 |
| Low Forecast | $-0.17 | $-0.17 | $-0.23 | $-0.22 | $-0.34 | $-0.32 | $-0.30 | $-0.42 | $-0.36 | $-0.37 | $-0.39 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Black Diamond Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BDTX previous annual EPS of $NaN (undefined).
Black Diamond Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| PASG | Passage Bio | $0.51 | $6.00 | 1076.47% | Buy |
| BDTX | Black Diamond Therapeutics | $2.43 | $14.75 | 507.00% | Buy |
| ADAP | Adaptimmune Therapeutics | $0.66 | $2.83 | 328.79% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| STOK | Stoke Therapeutics | $11.31 | $30.60 | 170.56% | Buy |
| ALEC | Alector | $3.64 | $4.00 | 9.89% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $57.07 | $60.63 | 6.24% | Buy |